Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) Shares Outstanding (Weighted Average): 2022-2025

Historic Shares Outstanding (Weighted Average) for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to $272.8 million.

  • Taysha Gene Therapies' Shares Outstanding (Weighted Average) rose 33.11% to $272.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $272.8 million, marking a year-over-year increase of 33.11%. This contributed to the annual value of $205.0 million for FY2024, which is 9.65% up from last year.
  • Per Taysha Gene Therapies' latest filing, its Shares Outstanding (Weighted Average) stood at $272.8 million for Q3 2025, which was up 27.08% from $214.7 million recorded in Q2 2025.
  • In the past 5 years, Taysha Gene Therapies' Shares Outstanding (Weighted Average) registered a high of $272.8 million during Q3 2025, and its lowest value of $38.5 million during Q1 2022.
  • Over the past 3 years, Taysha Gene Therapies' median Shares Outstanding (Weighted Average) value was $187.0 million (recorded in 2024), while the average stood at $169.6 million.
  • Data for Taysha Gene Therapies' Shares Outstanding (Weighted Average) shows a peak YoY spiked of 217.91% (in 2024) over the last 5 years.
  • Over the past 4 years, Taysha Gene Therapies' Shares Outstanding (Weighted Average) (Quarterly) stood at $62.4 million in 2022, then skyrocketed by 199.41% to $187.0 million in 2023, then grew by 9.65% to $205.0 million in 2024, then skyrocketed by 33.11% to $272.8 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $272.8 million for Q3 2025, versus $214.7 million for Q2 2025 and $214.7 million for Q1 2025.